Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Phuoc T Tran
Affiliation
University of Maryland School of Medicine
ORCID
Career Start Year
1996
Papers
207
H Index
49
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
37748118
Metastasis-Directed Therapy: A Moving Target Advancing Progress Forward.
J Clin Oncol
2024
37558543
Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
Eur Urol Oncol
2024
36316967
The impact of salvage radiotherapy initiation at PSA⿿⿤⿿0.5⿿ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
Prostate
2023
37566929
Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer.
EBioMedicine
2023
37060201
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Cancer
2023
37173210
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
Eur Urol
2023
37137444
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.
Int J Radiat Oncol Biol Phys
2023
37364800
FLASH Effects Induced by Orthovoltage X-Rays.
Int J Radiat Oncol Biol Phys
2023
37331778
Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology.
Semin Radiat Oncol
2023
36752776
Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.
Mol Cancer Ther
2023
36717286
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Eur Urol
2023
36708787
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
Int J Radiat Oncol Biol Phys
2023
36596347
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
Int J Radiat Oncol Biol Phys
2023
36179990
External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
Int J Radiat Oncol Biol Phys
2023
36369671
Evaluating potential overuse of surveillance care in cancer survivors.
Cancer Med
2023
36367998
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
J Clin Oncol
2023
36283936
Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
Eur Urol Oncol
2023
34296383
Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial.
J Cancer Surviv
2022
35478055
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
Med Oncol
2022
35641349
Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001.
Eur Urol
2022
35657158
Genomic biomarkers to guide precision radiotherapy in prostate cancer.
Prostate
2022
36001857
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
J Clin Oncol
2022
36244393
From Idea to Clinical Practice: A Brief History of Oligometastatic Disease.
Int J Radiat Oncol Biol Phys
2022
36244387
Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?
Int J Radiat Oncol Biol Phys
2022
35923127
Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
Prostate
2022
36251389
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Cancer Res
2022
35014708
Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
Prostate
2022
35013522
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.
Prostate Cancer Prostatic Dis
2022
35058322
The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging.
J Nucl Med
2022
34990726
Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.
Radiother Oncol
2022
35050303
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
JAMA Oncol
2022
34731491
BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
J Pathol
2022
34302474
Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches.
J Natl Cancer Inst
2022
30836168
Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities.
Int J Radiat Oncol Biol Phys
2021
33570548
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
JAMA Oncol
2021
33713497
Twist1 is required for the development of UVB-induced squamous cell carcinoma.
Mol Carcinog
2021
33484754
The hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategies.
Cancer Lett
2021
33755233
What are survivorship care plans failing to tell men after prostate cancer treatment?
Prostate
2021
34902034
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
JAMA Netw Open
2021
34801437
Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.
Eur Urol Oncol
2021
34129855
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
Ann Oncol
2021
34273331
In Reply to Onal et al.
Int J Radiat Oncol Biol Phys
2021
33985797
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
Eur Urol
2021
34090651
Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer.
Semin Radiat Oncol
2021
34196715
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.
JAMA Netw Open
2021
33452011
(Oligo)metastasis as a Spectrum of Disease.
Cancer Res
2021
33451978
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
2021
33419682
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
Eur Urol
2021
32861817
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.
Int J Radiat Oncol Biol Phys
2021
32798608
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.
Int J Radiat Oncol Biol Phys
2021
1 - 50 of 207
Column Actions
Search
Recommended Authors
Soumyajit Roy
Rush University Medical Center
Career Start Year
2013
Number of shared co-authors
39
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year
2010
Number of shared co-authors
35
Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year
2010
Number of shared co-authors
78
John Thoms
Memorial University
Career Start Year
2008
Number of shared co-authors
12
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year
2008
Number of shared co-authors
12
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year
2007
Number of shared co-authors
11
Aruz Mesci
Juravinski Cancer Centre
Career Start Year
2006
Number of shared co-authors
3
Alan H Bryce
Mayo Clinic
Career Start Year
2006
Number of shared co-authors
28
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year
2005
Number of shared co-authors
8
Ananya Choudhury
University of Manchester and The Christie NHS Foundation Trust
Career Start Year
2004
Number of shared co-authors
28
Niven Mehra
Radboud university medical center
Career Start Year
2004
Number of shared co-authors
32
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year
2003
Number of shared co-authors
13
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year
2003
Number of shared co-authors
37
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year
2001
Number of shared co-authors
10
David T Miyamoto
Massachusetts General Hospital
Career Start Year
2000
Number of shared co-authors
12
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year
2000
Number of shared co-authors
30
Johann S de Bono
The Institute for Cancer Research
Career Start Year
1999
Number of shared co-authors
56
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year
1998
Number of shared co-authors
15
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year
1997
Number of shared co-authors
50
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year
1997
Number of shared co-authors
28
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year
1996
Number of shared co-authors
34
Stanley K Liu
Odette Cancer Centre, University of Toronto
Career Start Year
1995
Number of shared co-authors
11
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year
1994
Number of shared co-authors
25
Lance C Pagliaro
Mayo Clinic
Career Start Year
1993
Number of shared co-authors
16
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year
1993
Number of shared co-authors
28
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Career Start Year
1993
Number of shared co-authors
13
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year
1990
Number of shared co-authors
37
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year
1987
Number of shared co-authors
47
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year
1981
Number of shared co-authors
66
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year
1973
Number of shared co-authors
55
row(s) 1 - 30 of 30
Collaborators
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers
43
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers
41
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers
30
Curtiland Deville
Johns Hopkins University
Co-authored papers
29
Ryan Phillips
Johns Hopkins University
Co-authored papers
26
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers
26
Ashley E Ross
Northwestern University
Co-authored papers
26
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers
25
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers
22
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers
21
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers
20
Todd McNutt
Johns Hopkins University School of Medicine
Co-authored papers
18
Amar U Kishan
University of California los angeles
Co-authored papers
17
Piet Ost
Ghent University, GZA Ziekenhuizen
Co-authored papers
15
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers
15
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers
13
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers
13
Wolfgang Lilleby
Oslo University Hospital
Co-authored papers
12
Michael L Steinberg
University of California los angeles
Co-authored papers
11
Edward M Schaeffer
Northwestern University Feinberg School of Medicine
Co-authored papers
11
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers
11
Elai Davicioni
Veracyte Inc.
Co-authored papers
11
Channing J Paller
Johns Hopkins University School of Medicine
Co-authored papers
11
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers
11
Mario A Eisenberger
Johns Hopkins University
Co-authored papers
11
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers
11
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers
11
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers
10
Bradley J Stish
Mayo Clinic
Co-authored papers
10
Paul C Boutros
University of California los angeles
Co-authored papers
10
1 - 30